---
title: "Centros Não Identificados"
output: 
  md_document:
    variant: gfm  # GitHub-flavored Markdown (for better rendering on GitHub)
    preserve_yaml: true  # Keep YAML metadata in the output
params:
  db: ''
---

Você encontrará aqui a lista de centros ainda não identificados, dividos
por estudo. Caso você reconheça algum centro por meio do estudo em
andamento e da descrição, **clique no centro** que você será
redirecionado para um formulário para identificação dele.

Obrigado por colaborar!

**NCT05161195**: Estudo aberto, multicêntrico de extensão avaliando a
segurança a longo prazo do ribociclib com outros medicamentos para
pacientes em estudo global da Novartis que se beneficiam do tratamento
contínuo.

- [**CNI**: Novartis Investigative Site 01255-000, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05161195&location_id=NOVARTISINVESTIGATIVESITESAOPAULO01255000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Novartis%20Investigative%20Site%2001255-000%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT03937154**: (PROCLAIM) Estudo de fase 3, randomizado, controlado
por placebo e duplo-cego, avaliando romiplostim para tratar
trombocitopenia induzida por quimioterapia em pacientes com câncer de
pulmão, ovário ou mama.

- [**CNI**: Loema Instituto de Pesquisa Clinica e Consultores Ltda
  13010-001, Campinas, São
  Paulo](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT03937154&location_id=LOEMAINSTITUTODEPESQUISACLINICAECONSULTORESLTDACAMPINASSAOPAULO13010001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Loema%20Instituto%20de%20Pesquisa%20Clinica%20e%20Consultores%20Ltda%2013010-001%2C%20Campinas%2C%20S%C3%A3o%20Paulo&form_type=Identificar%20Centro)

**NCT04810078**: (CheckMate-67T) Estudo de fase 3 comparando Nivolumab
subcutâneo vs. intravenoso em pacientes com carcinoma de células renais
claras avançado após terapia sistêmica.

- [**CNI**: Local Institution - 0096 01327-0001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04810078&location_id=LOCALINSTITUTION0096SAOPAULO013270001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%200096%2001327-0001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT04960709**: (VOLGA) Estudo randomizado de fase III que avalia a
eficácia e segurança de Durvalumab com Tremelimumab e Enfortumab Vedotin
ou Durvalumab com Enfortumab Vedotin em pacientes com câncer de bexiga
inelegíveis para cisplatina.

- [**CNI**: Research Site 03162-065, Săo Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04960709&location_id=RESEARCHSITESAOPAULO03162065BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2003162-065%2C%20S%C4%83o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05043090**: (SAMETA) Estudo de Fase III comparando savolitinibe
mais durvalumabe versus sunitinibe e monoterapia com durvalumabe em
carcinoma de células renais papilar MET-driven, irressecável, localmente
avançado ou metastático.

- [**CNI**: Research Site 30120-320, Belo Horizonte,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05043090&location_id=RESEARCHSITEBELOHORIZONTE30120320BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2030120-320%2C%20Belo%20Horizonte%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05043090&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05048797**: (DESTINY-Lung04) Estudo de fase 3 comparando
Trastuzumab Deruxtecan ao tratamento padrão para tratamento de primeira
linha em pacientes com NSCLC com mutações HER2 Exon 19 ou 20.

- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05048797&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05070858**: (NIMBLE) Estudo que avalia a eficácia e segurança da
terapia combinada de pozelimab e cemdisiran e da monoterapia com
cemdisiran em pacientes com miastenia gravis generalizada sintomática.

- [**CNI**: Jordy Sinapse medicina LTDA 06655-250, Itapevi, Sao
  Paulo](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05070858&location_id=JORDYSINAPSEMEDICINALTDAITAPEVISAOPAULO06655250BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Jordy%20Sinapse%20medicina%20LTDA%2006655-250%2C%20Itapevi%2C%20Sao%20Paulo&form_type=Identificar%20Centro)

**NCT05211895**: (PACIFIC-8) Estudo fase III randomizado, duplo-cego de
durvalumab mais domvanalimab vs. placebo em adultos com NSCLC
irressecável estágio III após quimiorradiação à base de platina.

- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05211895&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01221-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05211895&location_id=RESEARCHSITESAOPAULO01221900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001221-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05221840**: (PACIFIC-9) Estudo de fase III, duplo-cego, avaliando
durvalumabe com oleclumabe ou monalizumabe em adultos com NSCLC
irressecável estágio III após quimiorradiação à base de platina.

- [**CNI**: Research Site 30380-090, Belo Horizonte,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05221840&location_id=RESEARCHSITEBELOHORIZONTE30380090BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2030380-090%2C%20Belo%20Horizonte%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05261399**: (SAFFRON) Estudo de Fase III comparando savolitinib
mais osimertinib à quimioterapia de platina em pacientes com NSCLC
mutado por EGFR e superexpressão de MET após osimertinib.

- [**CNI**: Research Site 20231-050, Rio De Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05261399&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20De%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 90540-140, Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05261399&location_id=RESEARCHSITEPORTOALEGRE90540140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2090540-140%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 35162-189, Ipatinga,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05261399&location_id=RESEARCHSITEIPATINGA35162189BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2035162-189%2C%20Ipatinga%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 41950-610, Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05261399&location_id=RESEARCHSITESALVADOR41950610BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2041950-610%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05301842**: (EMERALD-3) Estudo de fase III, randomizado, aberto,
comparando TACE com durvalumab, tremelimumab e lenvatinib versus TACE
isolado em pacientes com carcinoma hepatocelular locorregional.

- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05301842&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05477576**: (ACTION-1) Estudo de fase 1b/3 comparando RYZ101 com
tratamento padrão em pacientes com GEP-NETs avançados, inoperáveis,
SSTR+ após terapia com 177Lu-SSA.

- [**CNI**: Research Facility - , Brasília,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05477576&location_id=RESEARCHFACILITYBRASILIABRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Facility%20%20-%20%2C%20Bras%C3%ADlia%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Facility - , São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05477576&location_id=RESEARCHFACILITYSAOPAULOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Facility%20%20-%20%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Facility - , Rio De Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05477576&location_id=RESEARCHFACILITYRIODEJANEIROBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Facility%20%20-%20%2C%20Rio%20De%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05501886**: (VIKTORIA-1) Estudo de fase 3, aberto, comparando
gedatolisib com fulvestranto, com/sem palbociclibe, a terapias padrão em
câncer de mama avançado HR+/HER2- após tratamento com inibidor de
CDK4/6.

- [**CNI**: Juiz de Fora Eurolatino Research Center - , Minas Gerais,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05501886&location_id=JUIZDEFORAEUROLATINORESEARCHCENTERMINASGERAISBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Juiz%20de%20Fora%20Eurolatino%20Research%20Center%20%20-%20%2C%20Minas%20Gerais%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05514054**: (EMBER-4) Estudo de fase 3 randomizado comparando
Imlunestrant adjuvante à terapia endócrina padrão em pacientes com
câncer de mama precoce ER+, HER2- com alto risco de recidiva após 2-5
anos de terapia prévia.

- [**CNI**: Oncocentro de Minas Gerais 30180-060, Belo Horizonte, Minas
  Gera](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05514054&location_id=ONCOCENTRODEMINASGERAISBELOHORIZONTEMINASGERA30180060BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Oncocentro%20de%20Minas%20Gerais%2030180-060%2C%20Belo%20Horizonte%2C%20Minas%20Gera&form_type=Identificar%20Centro)

**NCT05556096**: Estudo multicêntrico de Fase 3 que avalia a segurança e
eficácia do ALXN1720 em adultos com miastenia gravis generalizada e
autoanticorpos contra AChR.

- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05556096&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 0438-002, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05556096&location_id=RESEARCHSITESAOPAULO0438002BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%200438-002%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05646862**: (INAVO121) Estudo multicêntrico fase III randomizado
comparando eficácia e segurança de Inavolisib mais Fulvestrant versus
Alpelisib mais Fulvestrant em câncer de mama HR-positivo, HER2-negativo,
PIK3CA-mutado.

- [**CNI**: NUPEC 30220-140, Belo Horizonte,
  MG](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05646862&location_id=NUPECBELOHORIZONTEMG30220140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20NUPEC%2030220-140%2C%20Belo%20Horizonte%2C%20MG&form_type=Identificar%20Centro)

**NCT05668988**: Estudo de Fase 3 comparando DZD9008 com quimioterapia à
base de platina como tratamento de primeira linha para NSCLC avançado
com mutação de inserção no Exon 20 do EGFR.

- [**CNI**: WK28 Investigative Site - , Cachoeiro De Itapemirim,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITECACHOEIRODEITAPEMIRIMBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Cachoeiro%20De%20Itapemirim%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITEPORTOALEGREBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , Recife,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITERECIFEBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Recife%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , Rio De Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITERIODEJANEIROBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Rio%20De%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITESAOPAULOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , Natal,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITENATALBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Natal%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05687266**: (AVANZAR) Estudo global de Fase III comparando
Datopotamab Deruxtecan com durvalumab e carboplatina versus
pembrolizumabe com quimioterapia à base de platina no tratamento de
primeira linha de NSCLC avançado sem alterações genômicas.

- [**CNI**: Research Site 09323-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05687266&location_id=RESEARCHSITESAOPAULO09323900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2009323-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05687266&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05687266&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05774951**: (CAMBRIA-1) Estudo de fase III aberto comparando
camizestrant à terapia endócrina padrão em pacientes com câncer de mama
precoce ER+/HER2- com risco intermediário/alto de recidiva pós-terapia
locorregional.

- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05774951&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 22290-160, Rio De Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05774951&location_id=RESEARCHSITERIODEJANEIRO22290160BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2022290-160%2C%20Rio%20De%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05774951&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 40110-060, Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05774951&location_id=RESEARCHSITESALVADOR40110060BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2040110-060%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05794906**: (ARASTEP) Estudo de fase 3, randomizado e duplo-cego,
comparando darolutamida mais ADT versus placebo mais ADT em homens com
recorrência bioquímica de alto risco de câncer de próstata.

- [**CNI**: Hospital Evangélico de Cachoeiro de Itapemirim 29047-660,
  Vitória, Espírito
  Santo](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05794906&location_id=HOSPITALEVANGELICODECACHOEIRODEITAPEMIRIMVITORIAESPIRITOSANTO29047660BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Hospital%20Evang%C3%A9lico%20de%20Cachoeiro%20de%20Itapemirim%2029047-660%2C%20Vit%C3%B3ria%2C%20Esp%C3%ADrito%20Santo&form_type=Identificar%20Centro)

**NCT05827016**: (EXCALIBER-Maintenance) Estudo de fase 3 randomizado
comparando iberdomide vs. lenalidomide como manutenção pós-ASCT em
pacientes com mieloma múltiplo recém-diagnosticado.

- [**CNI**: Local Institution - 0096 21941-913, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05827016&location_id=LOCALINSTITUTION0096RIODEJANEIRO21941913BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%200096%2021941-913%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Local Institution - 0098 40110-150, Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05827016&location_id=LOCALINSTITUTION0098SALVADOR40110150BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%200098%2040110-150%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05907122**: Estudo randomizado duplo-cego avaliando a similaridade
farmacocinética do ABP 206 em comparação com OPDIVO® em pacientes com
melanoma ressecado em estágio III/IV no cenário adjuvante.

- [**CNI**: Hospital e Maternidade Brasil CEP 04501-000, Sao Paulo, São
  Paulo](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05907122&location_id=HOSPITALEMATERNIDADEBRASILSAOPAULOSAOPAULOCEP04501000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Hospital%20e%20Maternidade%20Brasil%20CEP%2004501-000%2C%20Sao%20Paulo%2C%20S%C3%A3o%20Paulo&form_type=Identificar%20Centro)

**NCT05952557**: (CAMBRIA-2) Estudo de fase III aberto comparando
camizestrant à terapia endócrina padrão em pacientes com câncer de mama
precoce ER+/HER2- com risco intermediário-alto ou alto de recidiva após
tratamento locorregional.

- [**CNI**: Research Site 58013-140, Joao Pessoa,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952557&location_id=RESEARCHSITEJOAOPESSOA58013140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2058013-140%2C%20Joao%20Pessoa%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 74000-000, Goiânia,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952557&location_id=RESEARCHSITEGOIANIA74000000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2074000-000%2C%20Goi%C3%A2nia%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 71615-907, Brasília,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952557&location_id=RESEARCHSITEBRASILIA71615907BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2071615-907%2C%20Bras%C3%ADlia%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952557&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05984277**: (eVOLVE-Lung02) Estudo global de Fase III comparando
volrustomig mais quimioterapia com pembrolizumab mais quimioterapia para
tratamento de primeira linha em pacientes com mNSCLC e PD-L1 \< 50%.

- [**CNI**: Research Site 90619-900, Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05984277&location_id=RESEARCHSITEPORTOALEGRE90619900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2090619-900%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06079671**: (eVOLVE-Cervical) Estudo de fase III, randomizado,
duplo-cego, controlado por placebo de volrustomig em mulheres com câncer
cervical localmente avançado de alto risco após quimiorradiação à base
de platina.

- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06079671&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 90619-900, Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06079671&location_id=RESEARCHSITEPORTOALEGRE90619900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2090619-900%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06097728**: (eVOLVE-Meso) Estudo global de fase III, randomizado e
aberto, comparando Volrustomig com Carboplatina e Pemetrexed versus
tratamentos padrão em pacientes com mesotelioma pleural irressecável.

- [**CNI**: Research Site 58013-140, Joao Pessoa,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06097728&location_id=RESEARCHSITEJOAOPESSOA58013140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2058013-140%2C%20Joao%20Pessoa%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06103864**: (TROPION-Breast05) Estudo de Fase III comparando
Dato-DXd com/sem durvalumabe versus quimioterapia mais pembrolizumabe em
pacientes com câncer de mama triplo-negativo metastático PD-L1 positivo.

- [**CNI**: Research Site 74000-000, Goiânia,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06103864&location_id=RESEARCHSITEGOIANIA74000000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2074000-000%2C%20Goi%C3%A2nia%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06109779**: (ARTEMIDE-Biliary01) Estudo global de Fase III
avaliando rilvegostomig com quimioterapia versus placebo como tratamento
adjuvante pós-reseção em pacientes com câncer de vias biliares.

- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06109779&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06112379**: (TROPION-Breast04) Estudo de Fase III comparando
Dato-DXd neoadjuvante mais durvalumab versus pembrolizumab mais
quimioterapia em pacientes com câncer de mama TNBC ou receptor hormonal
baixo/HER2-negativo não tratados.

- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06112379&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06120491**: (EvoPAR-Prostate01) Estudo de fase III, randomizado e
duplo-cego, avaliando Saruparib (AZD5305) com agentes hormonais versus
placebo em câncer de próstata metastático sensível à castração HRRm e
não-HRRm.

- [**CNI**: Research Site 41950-640, Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06120491&location_id=RESEARCHSITESALVADOR41950640BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2041950-640%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06129864**: (eVOLVE-HNSCC) Estudo de fase III randomizado
comparando volrustomig à observação em pacientes com carcinoma
espinocelular de cabeça e pescoço localmente avançado não ressecado após
quimiorradioterapia concomitante.

- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06129864&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06129864&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 35162-189, Ipatinga,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06129864&location_id=RESEARCHSITEIPATINGA35162189BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2035162-189%2C%20Ipatinga%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06129864&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06348199**: (SB27) Estudo de fase III, randomizado e duplo-cego,
comparando eficácia, segurança, farmacocinética e imunogenicidade do
SB27 vs. Keytruda em pacientes com NSCLC metastático não-escamoso.

- [**CNI**: SB Investigative Site - , Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06348199&location_id=SBINVESTIGATIVESITEPORTOALEGREBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20SB%20Investigative%20Site%20%20-%20%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: SB Investigative Site - , Florianópolis,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06348199&location_id=SBINVESTIGATIVESITEFLORIANOPOLISBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20SB%20Investigative%20Site%20%20-%20%2C%20Florian%C3%B3polis%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06357533**: (TROPION-Lung10) Estudo global de Fase III comparando
Dato-DXd com rilvegostomig ou rilvegostomig isolado versus pembrolizumab
no tratamento de primeira linha de NSCLC não escamoso avançado com alta
PD-L1.

- [**CNI**: Research Site 35162-189, Ipatinga,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06357533&location_id=RESEARCHSITEIPATINGA35162189BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2035162-189%2C%20Ipatinga%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 22211-230, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06357533&location_id=RESEARCHSITERIODEJANEIRO22211230BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2022211-230%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06380751**: (EvoPAR-Breast01) Estudo de fase III randomizado
comparando saruparib mais camizestrant versus inibidor de CDK4/6 mais
terapia endócrina em câncer de mama avançado com mutações BRCA1/2 ou
PALB2, HR-positivo, HER2-negativo.

- [**CNI**: Research Site 74000-000, Goiânia,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06380751&location_id=RESEARCHSITEGOIANIA74000000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2074000-000%2C%20Goi%C3%A2nia%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06380751&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06452277**: (SOHO-02) Estudo de fase 3 comparando BAY 2927088 oral
com tratamento padrão em pacientes com NSCLC avançado e mutações HER2.

- [**CNI**: Centro de Pesquisa da Clínica de Oncologia Reichow
  89010-340, Blumenau,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06452277&location_id=CENTRODEPESQUISADACLINICADEONCOLOGIAREICHOWBLUMENAU89010340BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Centro%20de%20Pesquisa%20da%20Cl%C3%ADnica%20de%20Oncologia%20Reichow%2089010-340%2C%20Blumenau%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06472076**: (GALAXIES Lung-301) Estudo de fase 3, randomizado e
duplo-cego, comparando belrestotug mais dostarlimab versus pembrolizumab
mais placebo em pacientes com NSCLC PD-L1 alto, não ressecável e
avançado não tratados.

- [**CNI**: GSK Investigational Site 60336-232, Fortaleza,
  Ceará](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06472076&location_id=GSKINVESTIGATIONALSITEFORTALEZACEARA60336232BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20GSK%20Investigational%20Site%2060336-232%2C%20Fortaleza%2C%20Cear%C3%A1&form_type=Identificar%20Centro)

**NCT02960022**: Estudo de extensão de fase 2 aberto coletando dados de
segurança a longo prazo para pacientes com câncer de próstata
beneficiando-se de Enzalutamida após participação em estudo clínico
anterior.

- [**CNI**: Site BR55008 - , Campinas,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT02960022&location_id=SITEBR55008CAMPINASBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Site%20BR55008%20%20-%20%2C%20Campinas%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT03899155**: (NA) Estudo observacional de longo prazo avaliando a
segurança do nivolumab e outras terapias contra o câncer em pacientes de
ensaios BMS em vários tipos de tumor.

- [**CNI**: Local Institution - 0355 01327-001, Sao Paulo,
  SP](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT03899155&location_id=LOCALINSTITUTION0355SAOPAULOSP01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%200355%2001327-001%2C%20Sao%20Paulo%2C%20SP&form_type=Identificar%20Centro)

**NCT04379596**: (DESTINY-Gastric-03) Estudo multicêntrico de Fase 1b/2
avaliando segurança, tolerabilidade e atividade antitumoral de
Trastuzumab Deruxtecan isolado ou com quimioterapia/imunoterapia em
câncer gástrico HER2-expressante.

- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04379596&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 045202-001, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04379596&location_id=RESEARCHSITESAOPAULO045202001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20045202-001%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04379596&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT04482309**: (DESTINY-PanTumor02) Estudo multicêntrico de Fase 2 que
avalia a eficácia e segurança do trastuzumab deruxtecan no tratamento de
tumores HER2-expressivos selecionados em vários tipos de câncer.

- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04482309&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT04613596**: Estudo de Fase 2/3 avaliando adagrasib isolado e com
pembrolizumab versus pembrolizumab em pacientes com NSCLC avançado com
mutação KRAS G12C.

- [**CNI**: Local Institution - Unk015 90619-900, Porto Alegre, Rio
  Grande Do
  Sul](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04613596&location_id=LOCALINSTITUTIONUNK015PORTOALEGRERIOGRANDEDOSUL90619900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%20Unk015%2090619-900%2C%20Porto%20Alegre%2C%20Rio%20Grande%20Do%20Sul&form_type=Identificar%20Centro)
- [**CNI**: Local Institution - Unk003 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04613596&location_id=LOCALINSTITUTIONUNK003RIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%20Unk003%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05633667**: (VELOCITY-Lung) Estudo de plataforma de Fase 2
avaliando a segurança e eficácia de novas combinações de tratamento em
pacientes com NSCLC não tratados, previamente tratados e ressecáveis.

- [**CNI**: Centro Gaúcho Integrado de Oncologia Hematologia, Ensino e
  Pesquisa Ltda./Hospital Mãe de Deus,Substudy-03 90110-270, Porto
  Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05633667&location_id=CENTROGAUCHOINTEGRADODEONCOLOGIAHEMATOLOGIAENSINOEPESQUISALTDAHOSPITALMAEDEDEUSSUBSTUDY03PORTOALEGRE90110270BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Centro%20Ga%C3%BAcho%20Integrado%20de%20Oncologia%20Hematologia%2C%20Ensino%20e%20Pesquisa%20Ltda.%2FHospital%20M%C3%A3e%20de%20Deus%2CSubstudy-03%2090110-270%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Real e Benemérita Associação Portuguesa de
  Beneficência/Hospital Beneficência Portuguesa de São Paulo (Hospital
  BP),Substudy-03 1509, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05633667&location_id=REALEBENEMERITAASSOCIACAOPORTUGUESADEBENEFICENCIAHOSPITALBENEFICENCIAPORTUGUESADESAOPAULOHOSPITALBPSUBSTUDY03SAOPAULO1509BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Real%20e%20Benem%C3%A9rita%20Associa%C3%A7%C3%A3o%20Portuguesa%20de%20Benefic%C3%AAncia%2FHospital%20Benefic%C3%AAncia%20Portuguesa%20de%20S%C3%A3o%20Paulo%20%28Hospital%20BP%29%2CSubstudy-03%201509%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Fundação Antonio Prudente/A.C. Camargo Cancer
  Center,Substudy-03 1509, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05633667&location_id=FUNDACAOANTONIOPRUDENTEACCAMARGOCANCERCENTERSUBSTUDY03SAOPAULO1509BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Funda%C3%A7%C3%A3o%20Antonio%20Prudente%2FA.C.%20Camargo%20Cancer%20Center%2CSubstudy-03%201509%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05853575**: Estudo randomizado comparando dois regimes de dosagem
de adagrasib em pacientes previamente tratados com NSCLC com mutação
KRAS G12C.

- [**CNI**: Local Institution - 181 41950-610, Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05853575&location_id=LOCALINSTITUTION181SALVADOR41950610BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%20181%2041950-610%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05952024**: (ACRUE) Estudo de Fase II que avalia a segurança,
tolerabilidade e eficácia de acalabrutinibe e rituximabe em pacientes
idosos ou frágeis não tratados com linfoma difuso de grandes células B.

- [**CNI**: Research Site 14048-900, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952024&location_id=RESEARCHSITERIBEIRAOPRETO14048900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014048-900%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01229-010, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952024&location_id=RESEARCHSITESAOPAULO01229010BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001229-010%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 13060-803, Campinas,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952024&location_id=RESEARCHSITECAMPINAS13060803BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2013060-803%2C%20Campinas%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 04502-001, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952024&location_id=RESEARCHSITESAOPAULO04502001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2004502-001%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952024&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06295809**: (INTerpath-007) Estudo adaptativo de Fase 2/3
comparando V940 (mRNA-4157) mais pembrolizumab versus tratamento padrão
em pacientes com carcinoma espinocelular cutâneo localmente avançado
ressecável.

- [**CNI**: Associação Hospitalar Beneficente São Vicente de
  Paulo-Instituto do Câncer ( Site 1309) 99010-080, Passo Fundo, Rio
  Grande Do
  Sul](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06295809&location_id=ASSOCIACAOHOSPITALARBENEFICENTESAOVICENTEDEPAULOINSTITUTODOCANCERSITE1309PASSOFUNDORIOGRANDEDOSUL99010080BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Associa%C3%A7%C3%A3o%20Hospitalar%20Beneficente%20S%C3%A3o%20Vicente%20de%20Paulo-Instituto%20do%20C%C3%A2ncer%20%28%20Site%201309%29%2099010-080%2C%20Passo%20Fundo%2C%20Rio%20Grande%20Do%20Sul&form_type=Identificar%20Centro)

**NCT06638931**: (ANTARES) Estudo de fase II tipo basket que avalia a
eficácia tecidual-agnóstica do nivolumabe em pacientes com tumores raros
avançados expressando PD-L1, focando em resposta e desfechos de
sobrevivência.

- [**CNI**: Hospital Santa Cruz 80420-090, Curitiba,
  Paraná](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06638931&location_id=HOSPITALSANTACRUZCURITIBAPARANA80420090BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Hospital%20Santa%20Cruz%2080420-090%2C%20Curitiba%2C%20Paran%C3%A1&form_type=Identificar%20Centro)
- [**CNI**: DF Star 70390-903, Brasília,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06638931&location_id=DFSTARBRASILIA70390903BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20DF%20Star%2070390-903%2C%20Bras%C3%ADlia%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Hospital São Carlos 60170-170, Fortaleza,
  Ceará](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06638931&location_id=HOSPITALSAOCARLOSFORTALEZACEARA60170170BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Hospital%20S%C3%A3o%20Carlos%2060170-170%2C%20Fortaleza%2C%20Cear%C3%A1&form_type=Identificar%20Centro)
- [**CNI**: IDOR Recife 52010-010, Recife,
  Pernambuco](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06638931&location_id=IDORRECIFERECIFEPERNAMBUCO52010010BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20IDOR%20Recife%2052010-010%2C%20Recife%2C%20Pernambuco&form_type=Identificar%20Centro)

**NCT04152109**: (PICS) Avaliação do impacto do Passe Espírita na saúde
mental, física e qualidade de vida por meio de práticas integrativas no
Brasil.

- [**CNI**: Núcleo de Praticas Integrativas e Complementares 381000 000,
  Uberaba, Minas
  Gerais](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04152109&location_id=NUCLEODEPRATICASINTEGRATIVASECOMPLEMENTARESUBERABAMINASGERAIS381000000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20N%C3%BAcleo%20de%20Praticas%20Integrativas%20e%20Complementares%20381000%20000%2C%20Uberaba%2C%20Minas%20Gerais&form_type=Identificar%20Centro)

**NCT04142437**: (ON-TRK) Estudo observacional que avalia a eficácia e
tolerância do Larotrectinib em pacientes adultos e pediátricos com
câncer de fusão TRK localmente avançado ou metastático por 24 a 60
meses.

- [**CNI**: Many Locations - , Multiple Locations,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04142437&location_id=MANYLOCATIONSMULTIPLELOCATIONSBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Many%20Locations%20%20-%20%2C%20Multiple%20Locations%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT04236700**: Estudo que avalia a prevalência de lesões orais e
periorais em trabalhadores móveis de praia expostos ao sol, investigando
associações sociodemográficas, ocupacionais e de saúde geral.

- [**CNI**: Caio Vinicius Gonçalves Roman Torres 11015001, Santos,
  SP](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04236700&location_id=CAIOVINICIUSGONCALVESROMANTORRESSANTOSSP11015001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Caio%20Vinicius%20Gon%C3%A7alves%20Roman%20Torres%2011015001%2C%20Santos%2C%20SP&form_type=Identificar%20Centro)
- [**CNI**: Caio Torres 11045, Santos,
  SP](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04236700&location_id=CAIOTORRESSANTOSSP11045BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Caio%20Torres%2011045%2C%20Santos%2C%20SP&form_type=Identificar%20Centro)

**NCT05541341**: Estudo de registro prospectivo que avalia a eficácia e
segurança do Tisagenlecleucel em pacientes brasileiros com malignidades
de linfócitos B ao longo de 15 anos em três coortes.

- [**CNI**: Novartis Investigative Site 34006-059, Minas Gerais, Belo
  Horizonte](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05541341&location_id=NOVARTISINVESTIGATIVESITEMINASGERAISBELOHORIZONTE34006059BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Novartis%20Investigative%20Site%2034006-059%2C%20Minas%20Gerais%2C%20Belo%20Horizonte&form_type=Identificar%20Centro)
- [**CNI**: Novartis Investigative Site 04544-000, Sao Paulo,
  SP](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05541341&location_id=NOVARTISINVESTIGATIVESITESAOPAULOSP04544000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Novartis%20Investigative%20Site%2004544-000%2C%20Sao%20Paulo%2C%20SP&form_type=Identificar%20Centro)

**NCT06014580**: (MADONNA) Estudo que avalia características moleculares
e epidemiológicas do câncer endometrial no Brasil para entender a
frequência de doença avançada e melhorar os resultados dos pacientes.

- [**CNI**: Santa Casa de Misericórdia de Feira de Santana - , Feira De
  Santana,
  Bahia](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06014580&location_id=SANTACASADEMISERICORDIADEFEIRADESANTANAFEIRADESANTANABAHIABRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Santa%20Casa%20de%20Miseric%C3%B3rdia%20de%20Feira%20de%20Santana%20%20-%20%2C%20Feira%20De%20Santana%2C%20Bahia&form_type=Identificar%20Centro)

**NCT06117891**: (REFINE-IO) Estudo observacional que coleta dados sobre
a eficácia do tratamento em adultos com carcinoma hepatocelular
irressecável após atezolizumabe mais bevacizumabe ou outras combinações
1L-IO.

- [**CNI**: Many Locations - , Multiple Locations,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06117891&location_id=MANYLOCATIONSMULTIPLELOCATIONSBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Many%20Locations%20%20-%20%2C%20Multiple%20Locations%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06131424**: (iRetroBC) Estudo multicêntrico retrospectivo que
avalia a prevalência de HER2-baixo, características clínicas e
resultados de tratamento em pacientes com câncer de mama metastático
HER2-negativo após terapia sistêmica.

- [**CNI**: Research Site - , Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06131424&location_id=RESEARCHSITESAOPAULOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06230328**: (BRA-HEP) Estudo retrospectivo multicêntrico que
analisa perfis epidemiológicos, manejo clínico e sobrevivência de
pacientes brasileiros com carcinoma hepatocelular de 2017 a 2022.

- [**CNI**: Research Site - , Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITESALVADORBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Natal,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITENATALBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Natal%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITESAOPAULOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITEPORTOALEGREBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Florianopolis,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITEFLORIANOPOLISBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Florianopolis%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Vitoria,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITEVITORIABRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Vitoria%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Sao Bernardo do Campo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITESAOBERNARDODOCAMPOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Sao%20Bernardo%20do%20Campo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Recife,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITERECIFEBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Recife%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Curitiba,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITECURITIBABRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Curitiba%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Belo Horizonte,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITEBELOHORIZONTEBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Belo%20Horizonte%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITERIODEJANEIROBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Sao Jose do Rio Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITESAOJOSEDORIOPRETOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Sao%20Jose%20do%20Rio%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06491862**: (RACE-2L) Estudo retrospectivo revisando prontuários
médicos no Brasil para avaliar desfechos em pacientes com NSCLC não
escamoso após falha de quimioterapia à base de platina de 2017 a 2022.

- [**CNI**: Research Site 01333-010, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06491862&location_id=RESEARCHSITESAOPAULO01333010BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001333-010%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
